For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...

Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...

Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders ...

The use of viral vectors as gene delivery and vaccine vehicles has developed rapidly during the last two decades owing to several viral properties. Viruses can infect cells efficiently, often have a ...

Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Pharmaceutical Technology spoke with Tania Pereira Chilima, Deputy CTO at Univercells Technologies about their technology and how it can be used in viral vector manufacturing, which is needed for ...